Hengartner, Michael P. (2022). Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. Springer International Publishing.
doi:
10.1007/978-3-030-82587-4.
ISBN978-3-030-82586-7.
Hengartner MP (April 2020). "Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission". BMJ Evid Based Med. 25 (2): 46–48.
doi:
10.1136/bmjebm-2019-111161.
PMID30975717.
Hengartner MP, Plöderl M (April 2022). "Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression". BMJ Evid Based Med. 27 (2): 69–73.
doi:
10.1136/bmjebm-2020-111600.
PMID33593736.
S2CID231939760.
^
abHengartner, Michael P. (2022). Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. Springer International Publishing.
doi:
10.1007/978-3-030-82587-4.
ISBN978-3-030-82586-7.
Hengartner, Michael P. (2022). Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. Springer International Publishing.
doi:
10.1007/978-3-030-82587-4.
ISBN978-3-030-82586-7.
Hengartner MP (April 2020). "Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission". BMJ Evid Based Med. 25 (2): 46–48.
doi:
10.1136/bmjebm-2019-111161.
PMID30975717.
Hengartner MP, Plöderl M (April 2022). "Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression". BMJ Evid Based Med. 27 (2): 69–73.
doi:
10.1136/bmjebm-2020-111600.
PMID33593736.
S2CID231939760.
^
abHengartner, Michael P. (2022). Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. Springer International Publishing.
doi:
10.1007/978-3-030-82587-4.
ISBN978-3-030-82586-7.